ArticleNature communications2026

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Tadashi Manabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.